By Ben Butkus

Gen-Probe this week reported record clinical diagnostic sales in the fourth quarter of 2010, but a decrease in Q4 blood screening revenues, resulting in an overall 2 percent decline in fourth-quarter revenues.

The company also updated investors on the uptake of its recently launched Panther molecular diagnostics platform in Europe, and on plans for US commercialization and test menu build-out for the instrument.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.